As of 2024-12-12, the Relative Valuation of Inozyme Pharma Inc (INZY) is (22.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.96 USD, the upside of Inozyme Pharma Inc based on Relative Valuation is -859.9%.
The range of the Relative Valuation is (26.74) - (27.49) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.8x - 18.3x | 18.0x |
| Forward P/E multiples | 5.1x - 18.7x | 11.9x |
| Fair Price | (26.74) - (27.49) | (22.49) |
| Upside | -1003.3% - -1028.7% | -859.9% |
| Date | P/E |
| 2024-11-21 | -1.79 |
| 2024-11-20 | -1.86 |
| 2024-11-19 | -1.87 |
| 2024-11-18 | -1.92 |
| 2024-11-15 | -2.08 |
| 2024-11-14 | -2.28 |
| 2024-11-13 | -2.36 |
| 2024-11-12 | -2.50 |
| 2024-11-11 | -2.66 |
| 2024-11-08 | -2.68 |
| 2024-11-07 | -2.73 |
| 2024-11-06 | -2.82 |
| 2024-11-05 | -2.71 |
| 2024-11-04 | -2.94 |
| 2024-11-01 | -2.90 |
| 2024-10-31 | -2.86 |
| 2024-10-30 | -3.02 |
| 2024-10-29 | -3.08 |
| 2024-10-28 | -3.18 |
| 2024-10-25 | -3.19 |
| 2024-10-24 | -3.27 |
| 2024-10-23 | -3.26 |
| 2024-10-22 | -3.40 |
| 2024-10-21 | -3.52 |
| 2024-10-18 | -3.69 |
| 2024-10-17 | -3.43 |
| 2024-10-16 | -3.54 |
| 2024-10-15 | -3.58 |
| 2024-10-14 | -3.50 |
| 2024-10-11 | -3.45 |
| 2024-10-10 | -3.28 |
| 2024-10-09 | -3.40 |
| 2024-10-08 | -3.50 |
| 2024-10-07 | -3.48 |
| 2024-10-04 | -3.44 |
| 2024-10-03 | -3.37 |
| 2024-10-02 | -3.35 |
| 2024-10-01 | -3.34 |
| 2024-09-30 | -3.48 |
| 2024-09-27 | -3.45 |
| 2024-09-26 | -3.42 |
| 2024-09-25 | -3.43 |
| 2024-09-24 | -3.48 |
| 2024-09-23 | -3.50 |
| 2024-09-20 | -3.81 |
| 2024-09-19 | -3.85 |
| 2024-09-18 | -3.87 |
| 2024-09-17 | -3.88 |
| 2024-09-16 | -3.99 |
| 2024-09-13 | -3.99 |